

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) May 19, 2020

**YIELD10 BIOSCIENCE, INC.**

(Exact Name of Registrant as Specified in Its Charter)

**DELAWARE**

(State or Other Jurisdiction of Incorporation)

**001-33133**

(Commission File Number)

**04-3158289**

(IRS Employer Identification No.)

**19 Presidential Way, Woburn, Massachusetts**

(Address of Principal Executive Offices)

**01801**

(Zip Code)

**(617) 583-1700**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock	YTEN	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07 - Submission of Matters to a Vote of Security Holders.**

On May 19, 2020, Yield10 Bioscience, Inc. (the "Company") held its 2020 annual meeting of its stockholders (the "Annual Meeting"). As of March 23, 2020, the record date for the Annual Meeting, there were 1,923,184 shares of the Company's common stock outstanding and entitled to vote. At the Annual Meeting, the holders of 1,536,465 shares of the Company's common stock were present or represented by proxy, which represented 79.9% of the total shares entitled to vote at the Annual Meeting.

A summary of the matters voted upon by the stockholders at the Annual Meeting, each of which is described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 25, 2020, and the final voting results for each matter are set forth below.

**Proposal 1 - Election of Director:**

Stockholders reelected the nominee identified below as Class II director of the Company to hold office until the annual meeting of stockholders in 2023 and until his successor is elected and qualified, subject to his earlier death, resignation or removal. The voting results for the nominee were as follows:

<u>Name of Class II Director Nominee</u>	<u>Votes For</u>	<u>Votes Withheld</u>	<u>Broker Non-Votes</u>
Oliver P. Peoples, Ph.D.	1,016,717	26,981	492,767

**Proposal 2 - Approval of an Amendment to the Company's 2018 Stock Option and Incentive Plan:**

Stockholders approved an amendment to the Company's 2018 Stock Option and Incentive Plan. The voting results for the proposal were as follows:

<u>Votes For</u>	<u>Votes Against</u>	<u>Abstentions</u>
977,756	51,505	14,437

**Proposal 3 - Ratification of the Appointment of the Company's Independent Registered Public Accounting Firm:**

The selection of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020, was ratified, based on the following votes:

<u>Votes For</u>	<u>Votes Against</u>	<u>Abstentions</u>
1,497,721	31,866	6,878

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

YIELD10 BIOSCIENCE, INC.

Date: May 20, 2020

By: /s/ Oliver P. Peoples  
Oliver P. Peoples, Ph.D.  
President & Chief Executive Officer